Literature DB >> 27542620

Modification of TAK1 by O-linked N-acetylglucosamine facilitates TAK1 activation and promotes M1 macrophage polarization.

Dongmei Zhang1, Zhiwei Xu2, Tao Tao2, Xiaojuan Liu1, Xiaolei Sun1, Yuhong Ji3, Lijian Han4, Huiyuan Qiu4, Guizhou Zhu3, Yifen Shen3, Liang Zhu4, Aiguo Shen5.   

Abstract

Macrophages play many different roles in tissue inflammation and immunity, and the plasticity of macrophage polarization is closely associated with acute inflammatory responses. O-GlcNAcylation is an important type of post-translational modification, which subtly modulates inflammation responses. Transforming growth factor (TGF)-β-activated kinase 1 (TAK1) is a key serine/threonine protein kinase that mediates signals transduced by pro-inflammatory cytokines such as TGF-β, tumor necrosis factor (TNF), and interleukin-1 (IL-1). It is here reported that TGFβ-activated kinase (TAK1) is modified with N-acetylglucosamine (O-GlcNAc) on S427. Both IL-1 and osmotic stress, which are known as the TAK1-signaling inducers, significantly trigger the O-GlcNAcylation of TAK1 in macrophages. By overexpressing wild-type (WT) or S427A TAK1 mutant into macrophages, it was determined that O-GlcNAcylation of TAK1 on S427 is required for T187/S192 phosphorylation and full activation of TAK1 upon stimulation with IL-1α and NaCl. Aborting O-GlcNAcylation of TAK1 on S427 was found to inhibit the downstream JNK and nuclear factor-κB activation and reduce the final amount of cytokines produced in activated macrophages to a great extent. Results also showed that overexpression of the O-GlcNAcylation-deficient mutant of TAK1 promotes LPS-mediated apoptosis in macrophages. Importantly, TAK1 O-GlcNAcylation was found to promote M1 macrophage polarization in activated macrophages. Taken together, these data demonstrate that O-GlcNAcylation of TAK1 on S427 critically regulates the pro-inflammatory activation and M1 polarization of macrophages via modulation of the TAK1/JNK/NF-κB signaling pathway.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Macrophage; O-GlcNAcylation; Polarization; TGFβ-activated kinase 1 (TAK1)

Year:  2016        PMID: 27542620     DOI: 10.1016/j.cellsig.2016.08.008

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  7 in total

Review 1.  Protein O-GlcNAcylation: emerging mechanisms and functions.

Authors:  Xiaoyong Yang; Kevin Qian
Journal:  Nat Rev Mol Cell Biol       Date:  2017-05-10       Impact factor: 94.444

2.  TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.

Authors:  Ayako Kobayashi; Shinichi Kobayashi; Kosuke Miyai; Yukiko Osawa; Toshikatsu Horiuchi; Shoichiro Kato; Takaaki Maekawa; Takeshi Yamamura; Junichi Watanabe; Ken Sato; Hitoshi Tsuda; Fumihiko Kimura
Journal:  Int J Hematol       Date:  2017-10-12       Impact factor: 2.490

Review 3.  Post-Translational Modifications of the TAK1-TAB Complex.

Authors:  Yusuke Hirata; Miki Takahashi; Tohru Morishita; Takuya Noguchi; Atsushi Matsuzawa
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 5.923

Review 4.  O-GlcNAcylation in immunity and inflammation: An intricate system (Review).

Authors:  Yu Li; Mingzheng Xie; Lili Men; Jianling Du
Journal:  Int J Mol Med       Date:  2019-06-11       Impact factor: 4.101

Review 5.  Multifaceted roles of TAK1 signaling in cancer.

Authors:  Himadri Mukhopadhyay; Nam Y Lee
Journal:  Oncogene       Date:  2019-11-06       Impact factor: 9.867

Review 6.  Targeting Protein O-GlcNAcylation, a Link between Type 2 Diabetes Mellitus and Inflammatory Disease.

Authors:  Israel Olapeju Bolanle; Timothy M Palmer
Journal:  Cells       Date:  2022-02-17       Impact factor: 6.600

7.  Penta-o-galloyl-beta-d-Glucose (PGG) inhibits inflammation in human rheumatoid arthritis synovial fibroblasts and rat adjuvant-induced arthritis model.

Authors:  Sadiq Umar; Anil K Singh; Mukesh Chourasia; Stephanie M Rasmussen; Jeffrey H Ruth; Salahuddin Ahmed
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.